MedTrace Logo

Diabetic Macular Edema Asian Response (DEAR) Study: Biomarkers for Response to Aflibercept in Asian Patients With Center Involving DME

NCT03197480 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2019-04-22

No results posted yet for this study

Summary

To investigate whether ocular imaging and proteomic biomarkers; and systemic biochemical, metabolomic, and genetic biomarkers predict treatment response to intravitreal aflibercept in a cohort of patients with DME.

Conditions

Interventions

DRUG

Aflibercept Injection [Eylea]

All subjects will receive 4 monthly intravitreal injections of aflibercept

Sponsors & Collaborators

  • Santen Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Singapore Eye Research Institute

    collaborator OTHER

  • Singapore National Eye Centre

    lead OTHER_GOV

Principal Investigators

  • Gavin Tan · Singapore National Eye Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-17
Primary Completion
2020-12-31
Completion
2021-03-01
FDA Drug
Yes

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03197480 on ClinicalTrials.gov